Potentially Resectable Locally Advanced Malignant Tumors of Biliary System Clinical Trial
A Single-arm, Open, Phase II Clinical Study of Tislelizumab Combined With Lenvatinib and Gemox Regimen for Transformational Treatment of Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.
This is a single-arm, open, Phase II clinical study of Tislelizumab combined with lenvatinib and Gemox regimen for transformational treatment of potentially resectable locally advanced malignant tumors of biliary system.
|Source||Tianjin Medical University Cancer Institute and Hospital|
|Status||Not yet recruiting|
|Start date||September 17, 2021|
|Completion date||January 30, 2023|